ArticleCancers2024

Osimertinib as Second- and ≥Third-Line Treatment in Advanced and Recurrence EGFR-Mutant NSCLC Patients Harboring Acquired T790M Mutation.

Mu-Han Peng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.